Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes-Reference-Cited by-同舟云学术

Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes

Published:2011-11 Issue:11 Volume:13 Page:1145-1154
ISSN:1520-9156
Container-title:Diabetes Technology & Therapeutics
language:en
Short-container-title:Diabetes Technology & Therapeutics

Author:

DeYoung Mary Beth¹,MacConell Leigh¹,Sarin Viren²,Trautmann Michael²,Herbert Paul³

Affiliation:

1. Amylin Pharmaceuticals, Inc., San Diego, California.

2. Eli Lilly & Company, Indianapolis, Indiana.

3. Alkermes, Inc., Waltham, Massachusetts.

Publisher

Mary Ann Liebert Inc

Subject

Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://www.liebertpub.com/doi/pdf/10.1089/dia.2011.0050

Reference32 articles.

1. Incretin-based therapies for type 2 diabetes mellitus

2. Exenatide efficacy and safety: a systematic review

3. Exenatide: a review from pharmacology to clinical practice

4. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus

5. Clinical Studies of Liraglutide, a Novel, Once-Daily Human Glucagon-Like Peptide-1 Analog for Improved Management of Type 2 Diabetes Mellitus

Cited by 218 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review;Cureus;2024-09-01

2. Porous Silicon Microparticles Enable Sustained Release of GLP‐1R Agonist Peptides for the Treatment of Type 2 Diabetes;Advanced Therapeutics;2024-08-10

3. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists;Frontiers in Endocrinology;2024-07-24

4. Poly(l-threonine-co-l-threonine Succinate) Thermogels for Sustained Release of Lixisenatide;Biomacromolecules;2024-07-01

5. Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature;Archives of Dermatological Research;2024-05-25